Antiretroviral therapies have worked wonders suppressing HIV replication and its progression to AIDS, but their effectiveness is deteriorating due to the constant development of drug resistance in the virus. Now Yale researchers have shown their newly developed compounds maintain anti-HIV activity against drug-resistant mutants better than FDA-approved medications.
The new compounds work by inhibiting the function of a viral enzyme, called reverse transcriptase, which is essential for HIV replication. The researchers report in the online journal eLife that high resolution images of viral crystal structures reveal the new inhibitors bind to both the “wild-type” and the mutant forms of the reverse transcriptase.
Source: Read Full Article